Pancreatic Cancer Research

ResearcherPrinceton UniversityActive in the last 2 years

Joshua D. Rabinowitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1247-4727; OpenAlex author ID A5053467552. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Co-author DOI 10.1002/cncr.70343↗
  2. Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Co-author DOI 10.1002/cncr.70510↗
  3. A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors. Co-author DOI 10.1016/j.xcrm.2026.102770↗
  4. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  5. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Last author DOI 10.1016/j.medj.2021.12.008↗
  6. NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2021.109238↗
  7. Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer. Co-author DOI 10.7150/ijbs.60473↗
  8. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Co-author DOI 10.1158/1078-0432.ccr-17-1115↗
  9. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Last author DOI 10.1158/0008-5472.can-14-2211↗
  10. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 4 shared papers, 2022–2026 · strength 0.83
  2. Gayle Jameson · 3 shared papers, 2025–2026 · strength 0.71
  3. Erkut Hasan Borazanci · 3 shared papers, 2025–2026 · strength 0.71
  4. Drew Warren Rasco · 2 shared papers, 2026 · strength 0.51
  5. Diana L. Hanna · 2 shared papers, 2026 · strength 0.51
  6. Haiyong Han · 2 shared papers, 2022–2025 · strength 0.32
  7. Ronald M. Evans · 2 shared papers, 2022–2025 · strength 0.32
  8. Lifeng Yang · 2 shared papers, 2021–2022 · strength 0.24
  9. Derek Cridebring · 1 shared paper, 2026 · strength 0.22
  10. Richard C. Frank · 1 shared paper, 2026 · strength 0.22
  11. Angela Tatiana Alistar · 1 shared paper, 2026 · strength 0.22
  12. David J. Propper · 1 shared paper, 2025 · strength 0.20
  13. Michael T. Barrett · 1 shared paper, 2025 · strength 0.20
  14. Luke Daniel Rothermel · 1 shared paper, 2026 · strength 0.19
  15. Moeez Ghani Rathore · 1 shared paper, 2026 · strength 0.19
  16. Jonathan J. Hue · 1 shared paper, 2026 · strength 0.19
  17. Ali Vaziri Gohar · 1 shared paper, 2026 · strength 0.19
  18. Mehrdad Zarei · 1 shared paper, 2026 · strength 0.19
  19. Omid Hajihassani · 1 shared paper, 2026 · strength 0.19
  20. Jordan Michael Winter · 1 shared paper, 2026 · strength 0.19
  21. Wenyun Lu · 2 shared papers, 2015–2022 · strength 0.17
  22. Michel Nofal · 2 shared papers, 2015–2022 · strength 0.17
  23. Jurre J. Kamphorst · 3 shared papers, 2015–2017 · strength 0.15
  24. Tanya Schild · 1 shared paper, 2021 · strength 0.12
  25. John Blenis · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.